@FiercePharma: Derek Lowe's take on the GSK-won't-buy-AstraZeneca story. Hint: Fig Newtons figure in. More | Follow @FiercePharma
@EricPFierce: FDA says drugs shortages are down dramatically. Commissioner gives president credit. Really? Report | Follow @EricPFierce
> Indian genericsmaker Dr. Reddy's says it has received FDA approval to produce a knock-off of Roche's osteoporosis drug Boniva. Story
> The upside of Regeneron Pharmaceuticals' ($REGN) Arcalyst may not be enough to offset the risk of side effects, FDA staff reported today. Story
> Analysts are predicting Pfizer's ($PFE) experimental treatment for rheumatoid arthritis will get regulatory approval next week despite some significant risks. Story
> FDA orders Alexza Pharmaceuticals ($ALXA) to fix manufacturing issues before it will approve its NDA for Adasuve, a schizophrenic and bipolar disorder treatment. Story
> In a twist on the usual pharma deal, Affymetrix will actually pay $15 million less than its initial bid of $330 million in the buyout of eBionscience. Story
Biotech News
@FierceBiotech: Startup Bina Technologies tries Apple-like strategy in genomics field. Item | Follow @FierceBiotech
@JohnCFierce: Big week for Pfizer coming up, with tofacitinib panel. They need a win here to regain some R&D cred. Story | Follow @JohnCFierce
@RyanMFierce: Fumapharm AG shareholders take early payday on BG-12 interest in $761M Royalty Pharma deal. Release | Follow @RyanMFierce
@MarkHFierce: Scientists have identified a gene linked to a rare condition where babies are born minus a spleen. Release | Follow @MarkHFierce
> Bill calls for cancer clinical trials results to be reported--or else. News
> FDA whacks Alexza Pharma with CRL for Adasuve. Story
> Pfizer faces crucial panel vote on blockbuster hopeful tofacitinib. Article
Medical Devices News
@FierceMedDev: U.K. regulators toughen focus against counterfeit devices and drugs. More | Follow @FierceMedDev
> Qiagen snatches up maker of amniotic fluid detection test. News
> Retinal implants yield amazing results in U.K., China. More
> (Lack of) FDA device monitoring draws new scrutiny. Article
> U.K. regulators toughen focus against counterfeit devices and drugs. Story
And Finally... AstraZeneca's ($AZN) exiting CEO David Brennan may be a $65 million example of the Peter Principle, says the Philly.com health blog. Post